1. Home
  2. Analysis

Dacryostenosis acquired and drugs of ingredients of ethinyl estradiol; norgestimate (a real world drug study)


Summary:

Dacryostenosis acquired is reported only by a few people who take drugs with ingredients of ethinyl estradiol; norgestimate. This phase IV clinical study analyzes 16,228 people who have side effects while taking drugs with ingredients of ethinyl estradiol; norgestimate from the the FDA. Among them, 1 have Dacryostenosis acquired. Find out below who they are, when they have Dacryostenosis acquired and more.

Drug(s) considered in the study (i.e. both brand name and generic drugs): Estarylla, Mili, Mono-linyah, Norgestimate and ethinyl estradiol, Ortho cyclen-21, Ortho cyclen-28, Ortho tri-cyclen, Ortho tri-cyclen 21, Ortho tri-cyclen 28, Ortho tri-cyclen lo, Previfem, Sprintec, Tri lo sprintec, Tri-estarylla, Tri-linyah, Tri-lo-estarylla, Tri-lo-mili, Tri-mili, Tri-previfem, Tri-sprintec.

On Jun, 07, 2026

16,228 people reported to have side effects when taking drugs with ingredients of ethinyl estradiol; norgestimate.
Among them, 1 person (0.01%) has Dacryostenosis acquired

What is Dacryostenosis acquired?

Dacryostenosis acquired (obstruction of the nasolacrimal duct-acquired) is found to be associated with 196 drugs and 527 conditions by eHealthMe. Check the latest studies of Dacryostenosis acquired.

Number of reports submitted per year:

Could drugs with ingredients of ethinyl estradiol; norgestimate cause Dacryostenosis acquired?

Gender of people who have Dacryostenosis acquired when taking drugs with ingredients of ethinyl estradiol; norgestimate *:

  • female: 100 %
  • male: 0.0 %

Age of people who have Dacryostenosis acquired when taking drugs with ingredients of ethinyl estradiol; norgestimate *:

  • 0-1: 0.0 %
  • 2-9: 0.0 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 100 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 0.0 %

Conditions people have *:

You may use this to check any potential undetected conditions.

  1. Polycystic Ovary Disease (cysts in the ovaries that occurs when the follicle stops developing): 1 person, 100.00%
  2. Hypersensitivity: 1 person, 100.00%
  3. High Blood Pressure: 1 person, 100.00%
  4. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 100.00%
  5. Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 100.00%
  6. Dry Eyes (lack of adequate tears): 1 person, 100.00%

Other drugs people take *:

You may use this to check any potential interacting drugs.

  1. Xyzal: 1 person, 100.00%
  2. Spironolactone: 1 person, 100.00%
  3. Restasis: 1 person, 100.00%
  4. Nexium: 1 person, 100.00%
  5. Neurontin: 1 person, 100.00%
  6. Lisinopril: 1 person, 100.00%
  7. Flexeril: 1 person, 100.00%

Other side effects people have besides Dacryostenosis acquired *:

You may use this to check any potential undetected side effects.

  1. Eye Infection: 1 person, 100.00%
  2. Chalazion (cyst in the eyelid): 1 person, 100.00%

* Approximation only. Some reports may have incomplete information.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

How the study uses the data?

The study uses data from the FDA. It is based on ethinyl estradiol; norgestimate. All drugs that have the same active ingredients (e.g. brand name and generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.